Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Collyar: What's In It for Patients?

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Nov

Today In Oncology

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Collyar: What's In It for Patients?

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Pancreatic Cancer Mild Duct Dilation May Serve as Early Indicator in High-Risk Patients

Preliminary Activity of LuPSMA-IT Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis

Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer

SABR May Be Comparable to Surgery for Early-Stage NSCLC

MD Anderson Launches 2.5 Billion Philanthropic Campaign